Abstract 324P
Background
Cancer being a lethal disease, delay in treatment may be fatal. International organizations have come up with useful guidelines for cancer management. Still the availability of resources, infrastructure, state health policy, COVID incidence and approach of healthcare professionals differ. This study aims to find out the perception and approaches of Indian oncologists - which might prove to be useful in nation specific delivery of cancer care during COVID Pandemic.
Methods
After taking consent, a survey form was circulated online amongst oncologists (haemato/ radiation/ medical/ surgical) across the country and responses collected.
Results
79.2% oncologists represent private sector, 16.8% government sector. 50% oncologists were willing to postpone investigations for stable cancer patients. 42.6% willing to start treatment without knowing the COVID status, while 44.6% were against the idea and 12.9% were indecisive. 73% willing to perform surgery right away for operable nonemergency cases with a negative COVID status and rest 27 % willing to postpone surgery. Concurrent Chemoradiation (57%) was preferred over sequential approach (43%). Majority (53.5%) were comfortable prescribing chemotherapy via telemedicine. Asymptomatic COVID positive patients requiring chemotherapy 64.4% were willing to wait for the virus to resolve and then start therapy and 35.6% were suggesting some form of oral therapy and ongoing isolation. 89.1% preferred oral route if option present. 83.7 % preferred targeted therapy, 8.2% immunotherapy and rest went for other options. 93.1 % preferred day care chemotherapy during COVID and not admission. 61 % thought extended course of dexamethasone given as premedication during chemotherapy did not have a protective role for patients during COVID outbreak. Treatment initiation criteria in descending order - 39.6% stage of the disease, 36.6 % performance status, 22.8% COVID status and for rest it was the cost. 91% oncologists thought nurses were at a higher risk of exposure to COVID infection than the doctors. 54.5% were not taking anti COVID prophylaxis..
Conclusions
Greater homogeneity in practice was noticed amongst oncologists of a developing nation during COVID outbreak. The above information might be useful in policy making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session